TL118
A Phase 2 Study of TL118 for the Treatment of Patients With Solid Tumors Harboring NTRK Gene Fusions
What's the purpose of the trial?
The main objective of the study will be to evaluate the efficacy of TL118 in participants with solid tumors harboring NTRK gene fusions
Trial status
Accepting patients
Phase
Phase 2
Enrollment
60
Last Updated
2 weeks ago
Participating Centers
There are 2 centers participating in this trial. Enter a location below to find the closest center.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- TL118 is an oral tropomyosin receptor kinase inhibitor being studied for use in NTRK fusion positive cancer.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.